drugset
drugset / Trial / NCT04762589

RT001 in Amyotrophic Lateral Sclerosis

NCT04762589 ↗

Phase 2 Completed 43 enrolled Biojiva LLC
RandomizedParallel-groupQuadruple-blindTreatment

Summary

RT001-014 is a Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Assess Efficacy, Long Term Safety and Tolerability of RT001 in Subjects with Amyotrophic Lateral Sclerosis

Timeline

Start
2021-03-10
Primary completion
2022-06-28
Completion
2022-06-28

Drugs

EvaluationDrugModalityDoseRoute
Subject RT001 Protein / enzyme biologic 5.76 g —

Indications

amyotrophic lateral sclerosis